Roddy Boyd of Storm King Reports makes the case that Intra-Cellular Therapies (ITCI) has failed to properly disclose a severe adverse reaction to its blockbuster drug, Caplyta. As one of the major players in the market for schizophrenia and bipolar I and II depression, Caplyta has a massive hidden safety signal that was curiously absent from its clinical trial data. What’s commonly referred to as drug-induced neuropathy, there’s been a growing number of reported cases of painful, occasionally debilitating, burning sensation. Roddy believes that the absence of this side effect on its drug label should raise more scrutiny and, if required to disclose such, it could lead to a meaningful decline in prescribed treatments. And considering this drug is at a higher price point, with less favorable treatment by insurance companies, Roddy believes there’s substantial risk to Intra-Cellular, given Caplyta is the company’s single commercially available product.